中國衞生集團(00673.HK)全年淨虧774.4萬港元 同比收窄78.89%
格隆匯6月30日丨中國衞生集團(00673.HK)發佈公吿,截至2021年3月31日止年度,公司實現收入8788.9萬港元,同比增長94.62%;公司股東應占虧損774.4萬港元,同比收窄78.89%;基本每股虧損0.19港仙,不派息。
2020年上半年,集團分銷及服務業務所在地武漢及湖北省周邊地區爆發新型冠狀病毒(COVID-19)疫情,不可避免地影響集團的業務。然而,受益於所處細分行業的優勢、與醫院客户及各廠商品牌良好的合作關係,馬格瑞茲(武漢)醫療技術發展有限公司("武漢馬格瑞茲",為集團業務主體)克服了重重困難,一方面大力拓展新的醫院客户,包括湖北省人民醫院、武漢大學中南醫院等一批頂級優質醫院;另一方面,與國內外知名廠商深度合作,引進了微創醫療科學有限公司等全新合作伙伴,並承接波士頓科學公司(BostonScientificCorporation)等廠商在華中地區的平台功能。
在上半年受疫情影響的背景下,在團隊的全力支援下,仍然取得銷售額的大幅增長。下半年,集團更積極把握行業復甦的機遇,擴大客户網路,增加產品數量,最終在全年取得滿意成績。集團的心血管器械及耗材分銷業務已初步建立其核心競爭力,即以武漢為中心,湖北為基礎,在華中地區建設大型三級醫院服務網路。
集團已與全球領先製造商建立穩健的戰略伙伴關係,併為心血管介入治療及外科手術的所有方面建立有影響力的區域供應鏈服務平台。監於分銷業務發展及市場增長潛力,年內,集團進一步增持武漢馬格瑞茲股權,股權由51%增至87.75%。該收購已於2021年5月完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.